CHRS - Coherus BioSciences, Inc. Stock Price and Quote

CHRS [NASD]

Index	-	P/E	-	EPS (ttm)	-3.76	Insider Own	2.03%	Shs Outstand	77.96M	Perf Week	8.98%
Market Cap	503.34M	Forward P/E	8.97	EPS next Y	0.72	Insider Trans	0.00%	Shs Float	71.61M	Perf Month	-4.60%
Income	-291.80M	PEG	-	EPS next Q	-0.63	Inst Own	-	Short Float / Ratio	16.83% / 10.50	Perf Quarter	3.38%
Sales	211.00M	P/S	2.39	EPS this Y	1.20%	Inst Trans	-1.54%	Short Interest	12.05M	Perf Half Y	-34.52%
Book/sh	-1.76	P/B	-	EPS next Y	146.80%	ROA	-53.80%	Target Price	17.12	Perf Year	-49.61%
Cash/sh	2.45	P/C	2.63	EPS next 5Y	-	ROE	477.10%	52W Range	5.58 - 14.11	Perf YTD	-18.81%
Dividend	-	P/FCF	-	EPS past 5Y	3.50%	ROI	-78.20%	52W High	-54.43%	Beta	0.96
Dividend %	-	Quick Ratio	2.50	Sales past 5Y	167.00%	Gross Margin	66.80%	52W Low	15.22%	ATR	0.40
Employees	359	Current Ratio	2.70	Sales Q/Q	-38.10%	Oper. Margin	-	RSI (14)	46.30	Volatility	3.85% 6.92%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-26.90%	Profit Margin	-	Rel Volume	0.99	Prev Close	6.48
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 06 AMC	Payout	-	Avg Volume	1.15M	Price	6.43
Recom	2.40	SMA20	0.67%	SMA50	-13.06%	SMA200	-23.84%	Volume	1,156,272	Change	-0.77%

Mar-28-23

Upgrade

UBS

Neutral → Buy

$11

Jun-14-22

Initiated

UBS

Neutral

Mar-07-22

Downgrade

JP Morgan

Overweight → Neutral

$15

Jul-16-20

Initiated

BofA Securities

Neutral

$20

Apr-17-20

Initiated

SunTrust

Buy

$26

Aug-13-19

Initiated

Mizuho

Buy

Aug-02-19

Reiterated

Maxim Group

Buy

$25 → $27

Aug-02-19

Reiterated

H.C. Wainwright

Buy

$28 → $29

Jun-11-19

Initiated

Barclays

Overweight

$30

May-07-19

Initiated

H.C. Wainwright

Buy

$28

Show Previous Ratings

Mar-29-23 03:30AM	6 analyst picks: Lululemon sparkles \| Pro Recap Investing.com
Mar-27-23 11:38AM	Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 64% over the last three years Simply Wall St.
Mar-08-23 06:59AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript Insider Monkey -5.48%
Mar-07-23 11:32AM	Q4 2022 Coherus BioSciences Inc Earnings Call Thomson Reuters StreetEvents +7.83%
Mar-06-23 05:15PM	Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:01PM	Loading…
04:01PM	Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results GlobeNewswire
08:00AM	FDA Approves UDENYCA® Autoinjector GlobeNewswire
Mar-01-23 08:25AM	Coherus BioSciences to Present at Upcoming Investor Conferences in March GlobeNewswire
Feb-28-23 08:25AM	Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 GlobeNewswire
Feb-15-23 08:25AM	Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma GlobeNewswire
Feb-13-23 08:25AM	Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services GlobeNewswire
Feb-03-23 05:30PM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire -5.25%
Jan-30-23 05:57PM	'Go big or go home': How a Peninsula biotech looks to win in Humira biosimilar 'feeding frenzy' American City Business Journals
Jan-09-23 08:20AM	Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma GlobeNewswire -6.26%
Jan-04-23 07:01AM	Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference GlobeNewswire +15.98%
07:12AM	Loading…
Jan-03-23 07:12AM	Should You Invest in Coherus BioSciences (CHRS)? Insider Monkey +7.45%
Dec-25-22 08:16AM	Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) GlobeNewswire
Dec-24-22 12:01AM	Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) GlobeNewswire
Dec-21-22 06:52AM	With 74% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns Simply Wall St.
Nov-10-22 06:18AM	Coherus BioSciences Third Quarter 2022 Earnings: Misses Expectations Simply Wall St. +11.70%
Nov-08-22 05:25PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:01PM	Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update GlobeNewswire
Nov-01-22 07:30AM	Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022 GlobeNewswire
Oct-18-22 10:48AM	Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 55% over the last three years Simply Wall St.
Oct-12-22 07:30AM	Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology GlobeNewswire
Oct-10-22 11:49AM	Will Coherus BioSciences (CHRS) Stock Bounce Back? Insider Monkey
Sep-19-22 07:30AM	Coherus to Launch CIMERLI (ranibizumab-eqrn) in the United States on October 3, 2022 GlobeNewswire
Sep-12-22 08:30AM	Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference GlobeNewswire
Sep-02-22 09:55AM	Here's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing Zacks -7.94%
Aug-29-22 08:49PM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
09:55AM	Loading…
Aug-19-22 09:55AM	Wall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet Zacks
Aug-06-22 05:00AM	Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript Motley Fool
Aug-04-22 05:25PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates Zacks +5.17%
04:01PM	Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update GlobeNewswire
Aug-03-22 09:55AM	Wall Street Analysts Predict an 85% Upside in Coherus BioSciences (CHRS): Here's What You Should Know Zacks
Aug-02-22 07:15PM	FDA Approves Coherus CIMERLI (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity GlobeNewswire +9.39%
Aug-01-22 11:15PM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire +8.15%
Jul-28-22 04:01PM	Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022 GlobeNewswire
Jul-18-22 10:59AM	Can This Small-Cap Biotech 5x Revenue by 2026? TheStreet.com
Jul-06-22 08:00AM	Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma GlobeNewswire
Jun-27-22 08:34AM	Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar? Zacks
Jun-22-22 04:30PM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
May-11-22 06:00PM	Coherus BioSciences Appoints Dr. Jill ODonnell-Tormey to its Board of Directors GlobeNewswire -9.04%
09:47AM	Shareholders in Coherus BioSciences (NASDAQ:CHRS) have lost 61%, as stock drops 12% this past week Simply Wall St.
May-10-22 08:45AM	Coherus BioSciences Management to Present at Upcoming Investor Conferences GlobeNewswire +6.10%
May-07-22 01:30AM	Coherus BioSciences (CHRS) Q1 2022 Earnings Call Transcript Motley Fool
May-05-22 05:35PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates Zacks -9.26%
04:01PM	Coherus BioSciences Reports First Quarter 2022 Results GlobeNewswire
08:31AM	Coherus BioSciences Appoints Charlie Newton to Board of Directors GlobeNewswire
May-03-22 09:45PM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
May-02-22 04:09PM	FDA rejects Peninsula biotech's cancer drug at least for now American City Business Journals +7.08%
09:22AM	FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer Benzinga
07:40AM	Coherus, Shanghai Junshi get complete response letter from the FDA for cancer therapy MarketWatch
07:00AM	Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA GlobeNewswire
Apr-29-22 04:01PM	CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022 GlobeNewswire
08:45AM	Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022 GlobeNewswire
Apr-28-22 03:02PM	Coherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-20-22 02:25PM	10 Biotech Stocks to Buy Today According to Kerr Neilsons Platinum Asset Management Insider Monkey
Apr-14-22 08:30AM	Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States GlobeNewswire
Apr-08-22 01:10PM	Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting GlobeNewswire
Apr-05-22 04:30PM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
06:59AM	7 Biotech Stocks to Buy With Key Catalysts for April InvestorPlace
Mar-29-22 09:15AM	Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event GlobeNewswire +6.60%
Mar-22-22 04:30PM	Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event GlobeNewswire
Mar-15-22 08:00AM	Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer GlobeNewswire
07:30AM	Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series GlobeNewswire
Mar-04-22 04:05PM	Coherus Management to Present at Upcoming Investor Conferences GlobeNewswire
08:00AM	Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell GlobeNewswire
Feb-18-22 12:00AM	Coherus BioSciences (CHRS) Q4 2021 Earnings Call Transcript Motley Fool
Feb-17-22 05:15PM	Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:01PM	Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results GlobeNewswire
Feb-15-22 04:30PM	Coherus Names Paul Reider Chief Commercial Officer GlobeNewswire
Feb-14-22 08:30AM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
Feb-11-22 08:30AM	Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022 GlobeNewswire
Feb-07-22 05:25PM	Amgen (AMGN) Beats Q4 Earnings Estimates Zacks
09:38AM	Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ... GuruFocus.com
08:30AM	Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors GlobeNewswire
Jan-10-22 07:30AM	Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody GlobeNewswire
Jan-07-22 08:30AM	Coherus BioSciences Secures Credit Financing with Pharmakon Advisors GlobeNewswire
Jan-04-22 08:32AM	Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-20-21 07:59AM	Coherus Announces U.S. FDA Approval of YUSIMRY (adalimumab-aqvh) GlobeNewswire
05:36AM	FDA Approves Coherus' Version of Abbvie's Humira, Best-Selling Drug in the U.S. TheStreet.com
Dec-17-21 09:09AM	Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer GlobeNewswire
Dec-16-21 04:30PM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
Dec-15-21 09:08PM	California public companies added more women than men to their boards in 2021. Here's why. American City Business Journals
Dec-13-21 07:00AM	Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer GlobeNewswire
07:00AM	Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer GlobeNewswire
Nov-18-21 06:45PM	103 of the 500 fastest growing tech companies are based in the Bay Area far more than in any other region American City Business Journals
Nov-16-21 09:08AM	Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer Zacks
Nov-15-21 08:30AM	Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer GlobeNewswire
08:30AM	Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer GlobeNewswire
Nov-11-21 05:46AM	Coherus BioSciences (NASDAQ:CHRS) shareholder returns have been notable, earning 72% in 3 years Simply Wall St.
Nov-10-21 04:15PM	Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire
Nov-08-21 10:00PM	Coherus BioSciences, inc (CHRS) Q3 2021 Earnings Call Transcript Motley Fool
05:25PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM	Coherus BioSciences Reports Third Quarter 2021 Results GlobeNewswire
Nov-05-21 08:30AM	Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022 GlobeNewswire
Nov-01-21 07:30AM	Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma GlobeNewswire
07:30AM	Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma GlobeNewswire
Oct-29-21 04:12PM	Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th GlobeNewswire

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience